OR5H15

Across TCGA pan-cancer cohorts, OR5H15 Mutation is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated OR5H15 data layer compared with 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher OR5H15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR5H15 expression acts as an unfavorable survival marker.

LUAD, BLCA, and LIHC are the cancer types where OR5H15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.124	0.670	<.001	18	view →
BLCA	DFS	Median	III,IV	0.124	0.572	.005	12	view →
LIHC	OS	Median	All	0.015	0.784	<.001	12	view →
LUSC	OS	Median	All	0.554	0.779	.018	10	view →
HNSC	OS	Median	II,III,IV	0.499	0.759	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OR5H15–LUAD (OS)

Open the LUAD breakdown →